Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses

Clinical Microbiology and Infection

Volumn 20, Issue 10, 2014, Pages O702-O710

  Matthijnssens, J ^a   Zeller, M ^a   Heylen, E ^a   De Coster, S ^a   Vercauteren, J ^a   Braeckman, T ^b   Van Herck, K ^b,c   Meyer, N ^d   Pircon J Y ^d   Soriano Gabarro, M ^e   Azou, M ^f   Capiau, H ^g   De Koster, J ^h   Maernoudt, A S ⁱ   Raes, M ^j   Verdonck, L ^g   Verghote, M ^k   Vergison, A ^l   Van Damme, P ^b   Van Ranst, M ^a   Adriaens, Filip ^m   Beulens, Bert ^m   Bochner, André ^m   Colpaert, Johan ^m   Bock, Jean De ^m   Gielen, Marie Laura ^m   Heyneman, An ^m   Michel, Marianne ^m   Matthijs, Inge ^m   Oosterlynck, Louis ^m   Pletincx, Michel ^m   Ryckaert, Ilse ^m   Sauvage, Annick ^m   Damme, Emmi Van ^m   Vlemincx, Ilse ^m   Watillon, Philippe ^m   more..

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d GSK   (Belgium)

^e BAYER PHARMA AG   (Germany)

^f Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

^g Paediatric Department AZ Alma   (Belgium)

^h DEPARTMENT OF CARDIOLOGY   (Belgium)

ⁱ Clinique Saint Pierre of Ottignies   (Belgium)

^j JESSA HOSPITAL   (Belgium)

^k Paediatric Department CHR Namur   (Belgium)

^l HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^m University Hospital for Children ^*

more..

Author keywords

Co infection; Disease severity; G2P 4 ; Rotavirus vaccine effectiveness; Selective pressure

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; ENTERIC VIRUS; GASTROENTERITIS; GENOTYPE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MIXED INFECTION; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ROTAVIRUS; VACCINATION; VIRUS DETECTION; BELGIUM; CASE CONTROL STUDY; CLASSIFICATION; CLINICAL TRIAL; COINFECTION; FECES; GENETICS; ISOLATION AND PURIFICATION; ROTAVIRUS INFECTIONS; VIROLOGY; VIRUS GENOME;

ROTAVIRUS;

BELGIUM; CASE-CONTROL STUDIES; COINFECTION; FECES; GASTROENTERITIS; GENOME, VIRAL; HOSPITALIZATION; HUMANS; PROSPECTIVE STUDIES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84913616422     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12612     Document Type: Article

References (37)

1. Estes M, Kapikian A. Rotaviruses. In: Knipe DM, Howley PM, Griffin DE et al., eds. Field's Virology, 5th edn. Philadelphia: Kluwer Health/Lippincott, Williams and Wilkins, 2007; 1917-1974.
2. Matthijnssens J, Heylen E, Zeller M, Rahman M, Lemey P, Van Ranst M. Phylodynamic analyses of rotavirus genotypes g9 and g12 underscore their potential for swift global spread. Mol Biol Evol 2010; 27: 2431-2436.
3. Matthijnssens J, Bilcke J, Ciarlet M et al. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol 2009; 4: 1303-1316.
4. Matthijnssens J, Ciarlet M, Heiman E et al. Full genome-based classification of rotaviruses reveals a common origin between human wa-like and porcine rotavirus strains and human ds-1-like and bovine rotavirus strains. J Virol 2008; 82: 3204-3219.
5. Nakagomi O, Nakagomi T, Akatani K, Ikegami N. Identification of rotavirus genogroups by RNA-RNA hybridization. Mol Cell Probes 1989; 3: 251-261.
6. Iturriza-Gomara M, Dallman T, Banyai K et al. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by Eurorotanet, a pan-European collaborative strain surveillance network. Epidemiol Infect 2010; 139: 895-909.
7. Matthijnssens J, Nakagomi O, Kirkwood CD, Ciarlet M, Desselberger U, Van Ranst M. Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes? Expert Rev Vaccines 2012; 11: 1347-1354.
8. Ward RL, Bernstein DI. Rotarix: a rotavirus vaccine for the world. Clin Infect Dis 2009; 48: 222-228.
9. ®. Virology 2010; 403: 111-127.
10. Phua KB, Lim FS, Lau YL et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27: 5936-5941.
11. Linhares AC, Velazquez FR, Perez-Schael I et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371: 1181-1189.
12. Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370: 1757-1763.
13. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (wc3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23-33.
14. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 11-22.
15. Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 606-614.
16. Zaman K, Dang DA, Victor JC et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 615-623.
17. Strategic Advisory Group of Experts SAGE. Meeting of the immunization strategic advisory group of experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009; 84: 220-236.
18. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011; 30: S21-S24.
19. Zeller M, Rahman M, Heylen E et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010; 28: 7507-7513.
20. Studie van de vaccinatiegraag bij jonge kinderen en adolescenten in vlaanderen in 2012 [in dutch], 2013. Available from: http://www.zorg-en-gezondheid.be/vaccinatiegraad/.
21. Macartney KK, Porwal M, Dalton D et al. Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J Paediatr Child Health 2011; 47: 266-270.
22. Paulke-Korinek M, Kundi M, Rendi-Wagner P et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011; 29: 2791-2796.
23. Lanzieri TM, Linhares AC, Costa I et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis 2011; 15: e206-e210.
24. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico. Pediatr Infect Dis J 2011; 30: S11-S15.
25. Becker-Dreps S, Paniagua M, Dominik R et al. Changes in childhood diarrhea incidence in Nicaragua following 3 years of universal infant rotavirus immunization. Pediatr Infect Dis J 2011; 30: 243-247.
26. Tate JE, Cortese MM, Payne DC et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011; 30: S56-S60.
27. Braeckman T, Van Herck K, Meyer N et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012; 345: e4752.
28. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22: 259-267.
29. Tregnaghi MW, Abate HJ, Valencia A et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30: e103-e108.
30. Kawamura N, Tokoeda Y, Oshima M et al. Efficacy, safety and immunogenicity of rix4414 in Japanese infants during the first two years of life. Vaccine 2011; 29: 6335-6341.
31. Li RC, Huang T, Li Y et al. Human rotavirus vaccine (rix4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Hum Vaccin Immunother 2013; 10: 11-18.
32. Steele AD, Neuzil KM, Cunliffe NA et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis 2012; 12: 213.
33. Adlhoch C, Hoehne M, Littmann M et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010-2011. Pediatr Infect Dis J 2013; 32: e82-e89.
34. Rolland M, Tovanabutra S, deCamp AC et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the step trial. Nat Med 2011; 17: 366-371.
35. Davies TA, Yee YC, Bush K, Sahm D, Evangelista A, Goldschmidt R. Effects of the 7-valent pneumococcal conjugate vaccine on u.S. Levofloxacin-resistant Streptococcus pneumoniae. Microb Drug Resist 2008; 14: 187-196.
36. Nakagomi T, Cuevas LE, Gurgel RG et al. Apparent extinction of non-g2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch Virol 2008; 153: 591-593.
37. ®, into the national immunization program of Australia. Pediatr Infect Dis J 2011; 30: S48-S53.